Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

650.39 -0.79 (-0.12%)

Streaming Delayed Price Updated: 2:46 PM EDT, Jul 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	598,494
Open	646.48
Bid (Size)	650.00 (80)
Ask (Size)	650.78 (120)
Prev. Close	651.18
Today's Range	637.80 - 655.20
52wk Range	541.00 - 821.11
Shares Outstanding	91,779,465
Dividend Yield	0.58%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Today 10:05 EDT

From Levi & Korsinsky, LLP

Via Business Wire

Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN

Today 10:00 EDT

San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on...

Via Newsfile

Performance

YTD	-16.2%	-16.2%
1 Month	+6.2%	+6.2%
3 Month	-12.9%	-12.9%
6 Month	-13.2%	-13.2%
1 Year	+15.9%	+15.9%

More News

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

Today 9:33 EDT

From Bernstein Liebhard LLP

Via GlobeNewswire

REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Today 7:06 EDT

From Faruqi & Faruqi, LLP

Via Business Wire

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

July 22, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law

July 21, 2026

From Bleichmar Fonti & Auld LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN

July 21, 2026

From Pomerantz LLP

Via GlobeNewswire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 21, 2026

From Schall Law

Via GlobeNewswire

REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

July 20, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

July 18, 2026

From DJS Law Group

Via Business Wire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 17, 2026

From The Schall Law Firm

Via Business Wire

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 17, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

July 17, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

3 High-Yield Dividend Stocks to Buy and Hold ↗

July 17, 2026

Via The Motley Fool

Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

July 16, 2026

From Robbins LLP

Via Business Wire

1 Large-Cap Stock with Exciting Potential and 2 We Turn Down

July 14, 2026

Via StockStory

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗

July 02, 2026

Via The Motley Fool

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗

July 01, 2026

Via The Motley Fool

Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗

June 29, 2026

Via Chartmill

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

Via The Motley Fool

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗

June 27, 2026

Via The Motley Fool

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

June 25, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Underrated Weight Loss Stocks to Buy and Hold ↗

June 23, 2026

Via The Motley Fool

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

June 22, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

This Stock Is Up 58% This Year. Is It too Late to Buy? ↗

June 17, 2026

Via The Motley Fool

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded.

What exchange does Regeneron Pharmaceuticals trade on?

Regeneron Pharmaceuticals trades on the Nasdaq Stock Market

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market

What is the current price of Regeneron Pharmaceuticals?

The current price of Regeneron Pharmaceuticals is 650.39

When was Regeneron Pharmaceuticals last traded?

The last trade of Regeneron Pharmaceuticals was at 07/23/26 02:46 PM ET

What is the market capitalization of Regeneron Pharmaceuticals?

The market capitalization of Regeneron Pharmaceuticals is 59.69B

How many shares of Regeneron Pharmaceuticals are outstanding?

Regeneron Pharmaceuticals has 60B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.